We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+8.44%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$1.48B
AUM Growth
+$175M
Cap. Flow
+$59.5M
Cap. Flow %
4.02%
Top 10 Hldgs %
38.11%
Holding
211
New
41
Increased
36
Reduced
32
Closed
77

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$10.3M
2
IOVA icon
Iovance Biotherapeutics
IOVA
+$9.84M
3
HOWL icon
Werewolf Therapeutics
HOWL
+$9.68M
4
ALT icon
Altimmune
ALT
+$9.34M
5
TWLO icon
Twilio
TWLO
+$9.2M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$49.7M
2
ABBV icon
AbbVie
ABBV
+$26.3M
3
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$12.9M
4
BMY icon
Bristol-Myers Squibb
BMY
+$12.6M
5
PANW icon
Palo Alto Networks
PANW
+$10.4M

Sector Composition

Rank Sector Weight
1 Healthcare 55.47%
2 Technology 8.46%
3 Industrials 4.82%
4 Financials 2.07%
5 Consumer Discretionary 1.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NKTX icon
51
Nkarta
NKTX
$150M
$8M 0.54%
252,478
+151,472
+150% +$4.36M
STTK icon
52
Shattuck Labs
STTK
$675M
$7.95M 0.54%
274,214
+133,549
+95% +$3.9M
ONTO icon
53
Onto Innovation
ONTO
$12.9B
$7.86M 0.53%
107,548
-17,452
-14% -$1.2M
STOK icon
54
Stoke Therapeutics
STOK
$1.8B
$7.85M 0.53%
233,135
+82,406
+55% +$2.91M
DYN icon
55
Dyne Therapeutics
DYN
$4.7B
$7.78M 0.53%
369,714
-80,350
-18% -$1.51M
MRTX
56
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$7.64M 0.52%
47,309
+17,530
+59% +$2.81M
IONS icon
57
CALL
Ionis Pharmaceuticals
IONS
$8.6B
$7.44M 0.5%
+186,600
New +$7.31M
BLSA
58
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$7.24M 0.49%
687,900
– –
ONC
59
BeOne Medicines Ltd
ONC
$32.8B
$7.17M 0.49%
20,900
– –
IDYA icon
60
IDEAYA Biosciences
IDYA
$3.42B
$7.03M 0.48%
334,794
+132,810
+66% +$2.73M
VRNT
61
DELISTED
Verint Systems
VRNT
$6.76M 0.46%
+150,000
New +$6.96M
ALT icon
62
Altimmune
ALT
$552M
$6.73M 0.46%
+683,395
New +$9.34M
NRIX icon
63
Nurix Therapeutics
NRIX
$2.41B
$6.48M 0.44%
244,157
+29,081
+14% +$854K
AGIO icon
64
CALL
Agios Pharmaceuticals
AGIO
$1.79B
$6.39M 0.43%
+116,000
New +$6.49M
MRUS
65
DELISTED
Merus
MRUS
$6.04M 0.41%
286,506
+209,514
+272% +$4.63M
RACB
66
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
$6M 0.41%
600,000
– –
ORTX
67
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$6M 0.41%
136,656
– –
ATER icon
68
Aterian
ATER
$4.45M
$5.85M 0.4%
33,333
+12,415
+59% +$2.9M
STRO icon
69
Sutro Biopharma
STRO
$401M
$5.48M 0.37%
29,483
– –
ALLT icon
70
Allot
ALLT
$372M
$5.48M 0.37%
276,187
-144,018
-34% -$2.65M
SPRY icon
71
ARS Pharmaceuticals
SPRY
$509M
$5.37M 0.36%
173,891
+6,092
+4% +$195K
ARYD
72
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
$5.36M 0.36%
500,000
– –
QURE icon
73
uniQure
QURE
$3.03B
$5.3M 0.36%
+172,000
New +$5.76M
VRNA
74
DELISTED
Verona Pharma
VRNA
$5.24M 0.35%
801,256
– –
FVRR icon
75
Fiverr
FVRR
$321M
$5.21M 0.35%
+21,500
New +$4.46M
1 2
3
4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q2 2021 Portfolio in Review

As of Q2 2021, Sphera Funds Management held 211 positions worth $1.48B, up 13% from $1.3B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Sphera Funds Management deployed $59.5M of net new capital in Q2 2021, opening 41 new positions and adding to 36 existing holdings. Its largest new stake was Iovance Biotherapeutics: 378,642 shares worth $9.85M.

By sector, the portfolio is most concentrated in Healthcare at 55% of assets, down from 63% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Eli Lilly, an estimated $49.7M trimmed.

  • Sphera Funds Management's largest Q2 2021 buy was Iovance Biotherapeutics: 378,642 shares worth $9.85M.
  • Sphera Funds Management added most to AstraZeneca in Q2 2021, an estimated $10.3M increase.
  • Sphera Funds Management's biggest Q2 2021 reduction was Eli Lilly, cutting an estimated $49.7M.
  • Sphera Funds Management fully exited Bristol-Myers Squibb in Q2 2021, selling an estimated $12.6M.
  • Sphera Funds Management's ten largest holdings make up 38% of its $1.48B portfolio in Q2 2021.
  • Sphera Funds Management opened 41 new positions and closed 77 in Q2 2021.
  • Sphera Funds Management's portfolio value rose 13% quarter-over-quarter to $1.48B.

Based on Sphera Funds Management's 13F filing for Q2 2021, filed 17 Aug 2021.